Backers included Boxer Capital of the Tavistock Group.
The company intends to use the proceeds to fund the completion of pre-clinical and early phase I clinical development of its LNA PCSK-9 drug, which it recently licensed from F.Hoffmann-La Roche and for the in-licensing of additional novel drugs to treat cardiometabolic diseases.
Founded in 2016 by CiVi Biopharma, Henrik Ørum, CiVi Biopharma focuses on creating novel therapies against cardiovascular and metabolic diseases. The company is incorporated in Delaware and has a wholly owned Danish subsidiary, CiVi Biopharma A/S, which is located in Hørsholm Science Park, Denmark.
The LNA PCSK-9 drug is based on Roche’s proprietary LNA drug technology, which enables scientists to develop drug-candidates against RNA targets, involved in a number of human diseases. The LNA PCSK-9 drug candidate further incorporates Roche’s proprietary GalNac targeting technology that directs the payload to the liver.